This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furge, K. A. Articles by Teh, B. T. Search for Related Content PubMed PubMed Citation Articles by Furge, K. A. Articles by Teh, B. T.

Detection of DNA Copy Number Changes and Oncogenic Signaling Abnormalities from Gene Expression Data Reveals MYC Activation in High-Grade Papillary Renal Cell Carcinoma

¹ Laboratory of Computational Biology, ² Cancer Genetics, and ³ Cytogenetics, Van Andel Research Institute; ⁴ Department of Urology, Spectrum Health Hospital, Grand Rapids, Michigan; ⁵ Department of Pathology, University Hospital Center Rijeka, Rijeka University School of Medicine, Rijeka, Croatia; and Departments of ⁶ Pathology and ⁷ Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

Requests for reprints: Bin Tean Teh, Laboratory of Cancer Genetics, Van Andel Research Institute, 333 Bostwick Avenue Northeast, Grand Rapids, MI 49503. Phone: 616-234-5296; Fax: 616-234-5297; E-mail: Bin.Teh{at}vai.org.

Papillary renal cell carcinoma (RCC) represents 10% to 15% of adult renal neoplasms; however, the molecular genetic events that are associated with the development and progression of sporadic papillary RCC remain largely unclear. Papillary RCCs can be divided into two subtypes based on histologic, cytogenetic, and gene expression differences. Type 1 tumors (60–70%) are generally low grade with favorable outcome, whereas type 2 tumors (30–40%) are associated with increased cytogenetic complexity, high tumor grade, and poor prognosis. In this study, computational analysis of gene expression data derived from papillary RCC revealed that a transcriptional signature indicative of MYC pathway activation is present in high-grade type 2 papillary RCC. The MYC signature is associated with amplification of chromosome 8q and overexpression of MYC that maps to chromosome 8q24. The importance of MYC activation was confirmed by both pharmacologic and short interfering RNA–mediated inhibition of active Myc signaling in a cell line model of type 2 papillary RCC. These results provide both computational and genetic evidence that activation of Myc is associated with the aggressiveness of papillary type 2 RCC. Therefore, it will be useful to consider inhibition of components of the MYC signaling pathway as avenues for therapeutic intervention in high-grade papillary RCC. [Cancer Res 2007;67(7):3171–6]

This article has been cited by other articles:

				S. L. Park, S.-C. Chang, L. Cai, C. Cordon-Cardo, B.-G. Ding, S. Greenland, S. K. Hussain, Q. Jiang, S. Liu, M.-L. Lu, et al. Associations between Variants of the 8q24 Chromosome and Nine Smoking-Related Cancer Sites Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3193 - 3202. [Abstract] [Full Text] [PDF]

				E. J. Kort, L. Farber, M. Tretiakova, D. Petillo, K. A. Furge, X. J. Yang, A. Cornelius, and B. T. Teh The E2F3-Oncomir-1 Axis Is Activated in Wilms' Tumor Cancer Res., June 1, 2008; 68(11): 4034 - 4038. [Abstract] [Full Text] [PDF]

				D. Huang, Y. Ding, W.-M. Luo, S. Bender, C.-N. Qian, E. Kort, Z.-F. Zhang, K. VandenBeldt, N. S. Duesbery, J. H. Resau, et al. Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis In vivo Cancer Res., January 1, 2008; 68(1): 81 - 88. [Abstract] [Full Text] [PDF]